Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Trial Identifier: D8223C00013
Sponsor: AstraZeneca
NCTID:: NCT04768985
Start Date: February 2021
Primary Completion Date: May 2021
Study Completion Date: May 2021
Condition: Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version

Trial Locations

Country Location
United States of America, CA Glendale, CA, United States of America, 91206
United States of America, MD Brooklyn, MD, United States of America, 21225
United States of America, UT Salt Lake City, UT, United States of America, 84107